Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    TripGift Launches Its Next-Generation Global Travel Value Platform

    September 8, 2026

    Egypt foreign reserves rise to record $57.2 billion

    September 8, 2026

    OMP Asia Conferences to Showcase How Industry Leaders Kraft Heinz, Mars, Medac, And Nestlé Approach AI-Powered Supply Chain Planning At “Decision Velocity”

    September 8, 2026
    Jerusalem GazetteJerusalem Gazette
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Jerusalem GazetteJerusalem Gazette
    Home » MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
    PR Newswire

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    February 14, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

    SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world’s first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    Revolutionizing Collagen Filler Technology

    SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body’s natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

    Why Recombinant Human Collagen?

    Highly Body-Friendly: SKINCOLLA’s recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

    With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

    Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

    Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it’s suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

    Cutting-Edge Technology for Long-Lasting Results

    The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

    Who Can Benefit from SKINCOLLA?

    SKINCOLLA is ideal for individuals seeking:

    Natural, subtle results without the “overdone” look often associated with traditional fillers.

    Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

    Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

    Indications for SKINCOLLA

    Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow’s feet, and marionette lines.

    Eyes: Dark circle reduction, eye wrinkles, and puffiness.

    Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

    For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact sales@maypharm.co.kr.

    Photo – https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/maypharm-co-ltd-launches-skincolla-the-worlds-first-recombinant-human-collagen-filler-for-superior-skin-rejuvenation-302376946.html


    Related Posts

    Cellebrite Announces Upcoming Investor Events in September

    September 4, 2026

    Cellebrite Guardian Completes IRAP Assessment: Achieves PROTECTED Level for Australian Government Agencies

    September 2, 2026

    Xinhua Silk Road: Hunan-Africa symbiosis, mutual endeavor — the Hunan model for China-Africa economic and trade cooperation

    September 2, 2026

    Cellebrite Federal Solutions, Inc. (CFSI) Achieves U.S. Department of War’s Advanced Cybersecurity Standard, Reinforcing Commitment to Secure Federal Operations

    September 1, 2026

    Cellebrite Brings Battlefield Intelligence to the Armed Forces with Launch of Portable Tactical Extraction Kit (C-TEK)

    August 26, 2026

    Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa

    August 25, 2026
    Editor's Pick

    Egypt foreign reserves rise to record $57.2 billion

    September 8, 2026

    Indonesia airports restart after Anak Krakatau volcanic ash

    September 8, 2026

    Air Arabia increases Bangkok frequency with four daily flights

    September 5, 2026

    UN Assembly votes to correct distorted world map projections

    September 5, 2026

    Korea Africa chart new course AI digital infrastructure summit

    September 5, 2026

    Korea Africa chart new course AI digital infrastructure summit

    September 5, 2026

    IFHC launches support initiative for UAE houbara breeders

    September 4, 2026

    WHO urges broader Congo Ebola response as cases reach 6,250

    September 4, 2026
    © 2026 Jerusalem Gazette | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.